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ST-elevation myocardial infarction with local infusion
of abciximab using thrombectomy catheter in a patient
with very late stent thrombosis
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Ab s t r a c t
A case of a 56-year-old male with a diagnosis of ST-segment elevation myocardial infarction caused by in-stent thrombosis in
a previously impanted bare metal stent after discontinuation of aspirin is presented. On admission there were ST segment elevations
in leads II, III, aVF with Q wave in III and aVF in the electrocardiogram. Three years before the admission patient had suffered from
inferior wall myocardial infarction and was treated successfully with primary percutaneous coronary intervention (PPCI) of the right
coronary artery with bare metal stent (BMS) implantation. Twelve months after the index PPCI patient stopped receiving all med-
ications including ASA. He felt he was in good health condition and did not need to take medications any longer. For the next 2 years
he had never visited doctor for follow-up visit. In current angiography occlusion of the right coronary artery with thrombus was iden-
tified. Patient was treated with aspiration thrombectomy which revealed large thrombus burden and with intralesion administration
of bolus of abciximab via thrombectomy catheter. Afterwards PCI with drug eluting stent implantation was performed. Patient was
discharged home after 5 days. At discharge his antiplatelet therapy consisted of acetylsalicylic acid (75 mg once daily) for life, and
clopidogrel (75 mg once daily, for at least 12 months). 
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S t r e s z c z e n i e
Przedstawiono przypadek 56-letniego pacjenta z zawałem serca z uniesieniem odcinka ST spowodowanego późną zakrzepicą
w stencie metalowym po odstawieniu leczenia przeciwpłykowego kwasem acetylosalicylowym. Przy przyjęciu do pracowni hemo-
dynamiki w zapisie elektrokardiograficznym obserwowano uniesienia odcinka ST o charakterze falii Pardeego w odprowadzeniach II,
III, aVF oraz patologiczne załamki Q w III i aVF. Trzy lata wcześniej pacjent miał wykonaną przezskórną interwencję wieńcową w zakre-
sie prawej tętnicy wieńcowej połączoną z implantacją stentu metalowego z powodu świeżego zawału serca. Zabieg wykonano opty-
malnie, przebiegł bez powikłań. Dwanaście miesięcy po przezskórnej interwencji wieńcowej chory przestał zażywać leki, w tym kwas
acetylosalicylowy, ponieważ czuł się dobrze. Przez następne 2 lata nie zażywał żadnych leków i nie był u kontroli u lekarza. W obec-
nym badaniu koronarograficznym stwierdzono zamknięcie prawej tętnicy wieńcowej z obecnością dużej skrzepliny. Zastosowano
trombektomię aspiracyjną systemem 6 F. W koszyczku uwidoczniono dużą ilość odessanego materiału zakrzepowego i zatorowego.
Następnie podano dowieńcowo bolus abciksimabu i uzyskano znaczącą redukcję skrzepliny. Ostatecznie wykonano przezskórną inter-
wencję wieńcową z implantacją stentu pokrytego lekiem. Pacjenta wypisano do domu po 5 dniach z zaleceniem zażywania kwasu
acetylosalicylowego w dawce 75 mg do końca życia oraz klopidogrelu w dawce 75 mg przez minimum 12 miesięcy. Planowa angio-
plastyka wieńcowa w zakresie krytycznie zwężonej gałęzi okalającej została zaplanowana 3–4 tygodnie później. 
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Introduction
Stent thrombosis although more rare with new
antiplatelet drugs (prasugrel, ticagrelor) but also improved
stent platforms is still a life-threatening issue in patients
after percutaneous coronary interventions (PCI) both with
drug-eluting and bare metal stents. In daily practice, how-
ever, it is not only confined to the first months or the first
year after the procedure but may unexpectedly occur at
a later time. Unfortunately, it is usually associated with
patient non-compliance to prescribed dual antiplatelet ther-
apy. 
We report a case of acute myocardial infarction caused
by late in-stent thrombosis successfully treated with
a combination of intralesional administration of abciximab
and thrombus aspiration with a thrombectomy device in
a patient who discontinued acetylsalicylic acid 1 year after
the initial PCI procedure with bare metal stent (BMS) im -
plantation.
Case report
A 56-year-old male patient was transferred directly from
his home by ambulance to our department with a work-
ing diagnosis of ST-segment elevation myocardial infarc-
tion (STEMI). He complained of a burning retrosternal chest
pain lasting approximately 11 h. There were ST segment
elevations in leads II, III and aVF with Q wave in III and aVF
in the electrocardiogram on admission (Fig. 1). The patient
was haemodynamically stable with minor crepitation over
lungs (Killip class II), with arterial blood pressure of 130/
85 mm Hg and regular pulse rate of 65 beats per minute.
His risk factors included arterial hypertension, hypercholes-
terolaemia and smoking habit. Three years before admis-
sion the patient had suffered from inferior wall myocardial
infarction and was treated successfully with primary per-
cutaneous coronary intervention (PPCI) of the right coro-
nary artery with BMS implantation. The final outcome
of that PPCI was optimal with TIMI 3 flow. The patient was
prescribed dual antiplatelet therapy with acetylsalicylic acid
(ASA) (75 mg once daily) for life and clopidogrel (75 mg
once daily) for 12 months. Twelve months after the index
PPCI the patient stopped receiving all medications including
ASA. He felt he was in a good health condition and did not
need to take medications any longer. For the next 2 years
he had never visited the doctor for a follow-up visit.
During the transfer by ambulance the patient received
300 mg of aspirin and 300 mg of clopidogrel. On admis-
sion to our cath lab 300 mg of clopidogrel were added on
top of previous medications. Immediate coronary angiog-
raphy using a right femoral access site and standard 
6 F diagnostic catheters was performed, revealing an acute
occlusion of the proximal right coronary artery (infarct-
related artery) with large thrombus burden probably caused
by in-stent thrombosis (Fig. 2 A). The remaining vessels
were normal with the exception of an 85% diameter steno-
sis in the circumflex artery. Percutaneous coronary inter-
vention of the infarct-related artery was started using
a Launcher (Medtronic Vascular, USA) 6 French Judkins right
4.0 guiding catheter. A bolus of unfractionated heparin was
administered (9000 IU). Appropriate anticoagulation 
was confirmed by activated clotting time measurement 
(> 250 s). The occlusion was crossed with a 0.014-inch Whis-
per ES (Abbott Vascular, USA) guidewire. Then three con-
secutive passages with Export aspiration catheter (Medtron-
ic Vascular, USA) were performed. Large thrombus debris
was visualized and retrieved from the coronary artery 
(Fig. 3). Partial flow was restored in the artery with a visible
remaining thrombus proximally to the previously implant-
ed stent with signs of restenosis and residual thrombus
(Fig. 2 B). At that point a standard bolus of abciximab (Reo-
Pro by Eli Lilly and Company) was administered through
the thrombectomy catheter slowly to the lesion. A signifi-
cant reduction of thrombus burden was observed (Fig. 2 C).
The continuous i.v. infusion of abciximab was continued
for 24 h. At that stage predilatation with a Maverick
(Boston Scientific, USA) balloon catheter 2.5 mm × 20 mm
Fig. 1. ECG on admission to cath lab
Ryc. 1. EKG przy przyjęciu do pracowni hemodynamiki
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Fig. 3. Thrombus debris
Fig. 3. Materiał zakrzepowy
Fig. 4. Final angiography of right coronary artery
Ryc. 4. Ostateczny wynik zabiegu w prawej tętnicy
wieńcowej
Fig. 2. A – Initial angiography of right coronary artery. B – Angiography after thrombectomy (previously implant-
ed stent is marked by arrow). C – Angiography after abciximab bolus infusion
Fig. 2. A – Wyjściowa angiografia prawej tętnicy wieńcowej. B – Angiografia po trombektomii (strzałką zaznaczono
poprzednio implantowany stent). C – angiografia po podaniu bolusa abciksimabu
A B C
at 18 atm was performed with transient slow-flow. Due to
persistent stenosis a BMS, Prokinetic (Biotronik, Germany)
4.0 mm × 15 mm, at 18 atm was implanted at the site
of the previous stent. The operator decided to implant
a BMS due to large vessel diameter and expected poor
patient compliance to the prescribed antiplatelet the rapy
(Fig. 4). After PCI the patient was symptom-free and peak
levels of cardiac markers after PCI were: CK 2359 IU/l, 
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CK-MB 248 IU/l and troponin T hs 3446 ng/ml (cut-off val-
ue 14 ng/ml). In the control echocardiogram the left ven-
tricular ejection fraction was 50% with akinesia of the infe-
rior wall. The patient was discharged home after 5 days.
At discharge his antiplatelet therapy consisted of ASA 
(75 mg once daily) for life, and clopidogrel (75 mg once dai-
ly, for at least 12 months). Percutaneous coronary inter-
vention of the circumflex artery was scheduled 3 weeks
after discharge.  
Discussion
In the real world scenario poor compliance to prescribed
antiplatelet therapy in patients after acute coronary syn-
dromes is quite common [1]. Although stent thrombosis is
more rare with new antiplatelet drugs (prasugrel, ticagrelor)
and improved stent platforms, it is still a life-threatening
issue in patients after PCI both with drug-eluting and bare
metal stent implantation [2]. The predicted probability
of stent thrombosis is not solely confined to drug eluting
stent (DES) because there are still reports of very late stent
thrombosis in BMS as well [3]. In the majority of cases
the discontinuation of dual antiplatelet therapy is blamed;
however, it seems that cessation of ASA routinely used as
secondary prevention years after STEMI might be delete-
rious as well. On the other hand, such late thrombosis
might be attributed to procedural flaws such as stent
underexpansion or poor neointimal healing. In our patient
it seems that both progression of the atherosclerosis (no
statin use) and thrombosis (no antiplatelet medications)
at the site of the previously implanted stent caused
the acute coronary syndrome (ACS).
The once debatable issue of DES use in STEMI patients
is now gone as the safety profile of new generation DES
and their performance in terms of efficacy is well proven
[4, 5]. The current European NSTEMI and updated ACC/AHA
STEMI guidelines recommend DES use on an individual
basis taking into account baseline characteristics and
bleeding risks; however, BMS use for suitable patients is
still an option [6]. In Poland the penetration of DES among
ACS patients is ca. 35%, which is fairly low in comparison
to other European countries.
The novel approach in our case is the use of intrale-
sional abciximab combined with already guideline-recom-
mended thrombus aspiration [6]. In some cases glycopro-
tein GP IIb/IIIa inhibitors such as abciximab are used as
an intravenous bolus followed by infusion during primary
PCI for STEMI as an adjunctive and efficient therapy [7].
There are still no convincing results proving the clinical
benefit of intracoronary over intravenous use of abciximab
in STEMI patients and the results of studies such as AIDA
STEMI are negative [8]. A new concept of intralesional
administration of abciximab directly to the thrombus by
a dedicated new balloon catheter (Clearway, Atrium, USA)
was tested in the INFUSE AMI trial [9]. Local administra-
tion of abciximab was associated with significant reduc-
tion of the infarct size assessed by cardiac magnetic reso-
nance at 30 days after the first, anterior wall STEMI in com-
parison to no abciximab, but the most pronounced bene-
fit was observed when local infusion of abciximab was
combined with prior thrombectomy. It seems that such
administration in vulnerable patients with a large throm-
bus burden might facilitate thrombectomy itself.  
In conclusion, both intralesional abciximab adminis-
tration and thrombus aspiration may be considered for
patients with an occluded artery with a high thrombus bur-
den, i.e. caused by stent thrombosis, but the efficacy
of such an algorithm still needs to be evidenced in large
clinical trials. 
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